Department of Information, Taian City Central Hospital, Taian, People's Republic of China.
Taian City Central Hospital, Taian, People's Republic of China.
Int J Gynecol Cancer. 2019 Jan;29(1):140-146. doi: 10.1136/ijgc-2018-000060.
Some clinical and basic research studies have indicated that exposure to metformin might have protective effects against ovarian cancer. However, results from epidemiologic studies have been inconsistent. We performed a meta-analysis to evaluate the effect of metformin use on the risk of ovarian cancer occurrence and mortality.
Multiple databases were searched to identify studies on the association between use of metformin and risk of ovarian cancer or prognosis, up to August 2018. Relevant information for analysis was extracted. A random-effects model was used to calculate the pooled risk estimate.
Thirteen articles were included, of which six articles focused on ovarian cancer incidence and the others focused on prognosis. The pooled OR for ovarian cancer occurrence and mortality comparing metformin use with non-use or use of other hypoglycemic drugs was 0.76 (95% CI 0.62 to 0.93, p = 0.008) and 0.55 (95% CI 0.36 to 0.84, p = 0.006), respectively. Moderate to substantial heterogeneity was observed across included studies.
Our findings demonstrate that use of metformin was significantly associated with a lower incidence and a better prognosis of ovarian cancer in patients with diabetes. Well-designed interventional studies are warranted to confirm our findings.
一些临床和基础研究表明，二甲双胍的暴露可能对卵巢癌具有保护作用。然而，来自流行病学研究的结果并不一致。我们进行了一项荟萃分析，以评估二甲双胍使用与卵巢癌发生和死亡率风险的关系。
我们检索了多个数据库，以确定关于二甲双胍使用与卵巢癌风险或预后之间关联的研究，截至 2018 年 8 月。提取了用于分析的相关信息。使用随机效应模型计算汇总风险估计。
共纳入 13 篇文章，其中 6 篇文章集中于卵巢癌的发生率，其余文章则集中于预后。与非使用或使用其他降血糖药物相比，使用二甲双胍的患者卵巢癌发生和死亡率的汇总 OR 分别为 0.76（95%CI 0.62 至 0.93，p = 0.008）和 0.55（95%CI 0.36 至 0.84，p = 0.006）。纳入的研究存在中度至高度异质性。
我们的研究结果表明，在患有糖尿病的患者中，使用二甲双胍与卵巢癌的发生率降低和预后改善显著相关。需要进行精心设计的干预性研究来证实我们的发现。
